CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This research aims to improve treatment outcomes for triple-negative breast cancer by studying microRNAs and their role in chemotherapy response. The project focuses on identifying biomarkers and enhancing treatment efficacy through innovative preclinical models.
Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer and therapies are primarily limited to conventional chemotherapy. TNBC patients who respond to neo-adjuvant chemotherapy with a pathological complete response (pCR) have excellent 5-year survival (up to 94%).
However, this represents the minority of TNBC patients (25-40%).
The remaining patients have less than 60% 5-year survival due to aggressive relapse.
Therefore, increasing the pCR rate of chemotherapy in TNBC…
BILKENT UNIVERSITESI VAKIF
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
